Scheen, André J.

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet

Diabetes Treatment and ManagementPeroxisome Proliferator-Activated Receptors

Cited by 4,129

Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes

Esser, N., Legrand-Poels, S., Piette, J., Scheen, A. J., & Paquot, N. (2014) · Diabetes Research and Clinical Practice

Adipokines, Inflammation, and Metabolic DiseasesAdipose Tissue and Metabolism

Cited by 1,981

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): A double-blind, randomised placebo-controlled trial

Hernandez, A. F., Green, J. B., Janmohamed, S., D'Agostino, R. B., Granger, C. B., Jones, N. P., Leiter, L. A., Rosenberg, A. E., Sigmon, K. N., Somerville, M. C., et al. (2018) · The Lancet

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 1,829

3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial

le Roux, C. W., Astrup, A., Fujioka, K., Greenway, F., Lau, D. C. W., Van Gaal, L., Ortiz, R. V., Wilding, J. P. H., Skjøth, T. V., Manning, L. S., et al. (2017) · The Lancet

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 850

Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial

Pieber, T. R., Bode, B., Mertens, A., Cho, Y. M., Christiansen, E., Hertz, C. L., Wallenstein, S. O. R., Buse, J. B., Akın, S., Aladağ, N., et al. (2019) · The Lancet Diabetes & Endocrinology

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 287

Weight Management in Type 2 Diabetes: Current and Emerging Approaches to Treatment

Van Gaal, L., & Scheen, A. (2015) · Diabetes Care

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 221

Free fatty acids as modulators of the NLRP3 inflammasome in obesity/type 2 diabetes

Legrand-Poels, S., Esser, N., L’homme, L., Scheen, A., Paquot, N., & Piette, J. (2014) · Biochemical Pharmacology

Inflammasome and immune disordersAdipokines, Inflammation, and Metabolic Diseases

Cited by 194

Cardiovascular effects of gliptins

Scheen, A. J. (2013) · Nature Reviews Cardiology

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 175

Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study.

Van Gaal, L. F., Scheen, A. J., Rissanen, A. M., Rössner, S., Hanotin, C., & Ziegler, O. (2008) · European Heart Journal

Pharmacology and Obesity TreatmentCannabis and Cannabinoid Research

Cited by 156

Effect of SGLT2 Inhibitors on the Sympathetic Nervous System and Blood Pressure

Scheen, A. J. (2019) · Current Cardiology Reports

Diabetes Treatment and ManagementBlood Pressure and Hypertension Studies

Cited by 122

Pharmacokinetics and Clinical Use of Incretin-Based Therapies in Patients with Chronic Kidney Disease and Type 2 Diabetes

Scheen, A. J. (2015) · Clinical Pharmacokinetics

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 102

Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease

Scheen, A. J. (2013) · Expert Opinion on Drug Metabolism & Toxicology

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 91

A randomized study over 13 cycles to assess the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on carbohydrate metabolism

Gaspard, U., Scheen, A., Endrikat, J., Buicu, C., Lefebvre, P., Gerlinger, C., & Heithecker, R. (2003) · Contraception

Reproductive Health and ContraceptionOvarian function and disorders

Cited by 72

SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment

Scheen, A. J. (2015) · Expert Opinion on Drug Safety

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 70

CB1 receptor blockade and its impact on cardiometabolic risk factors: overview of the RIO programme with rimonabant.

Scheen, A. J. (2008) · Journal of Neuroendocrinology

Pharmacology and Obesity TreatmentAdipokines, Inflammation, and Metabolic Diseases

Cited by 68

Reappraisal of the diuretic effect of empagliflozin in the EMPA-REG OUTCOME trial: Comparison with classic diuretics

Scheen, A. J. (2016) · Diabetes & Metabolism

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 64

Dual GIP/GLP-1 receptor agonists: new advances for treating type-2 diabetes

Scheen, A. J. (2023) · Annales d'Endocrinologie

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 63

The role of biochemical of bone turnover markers in osteoporosis and metabolic bone disease: a consensus paper of the Belgian Bone Club

Cavalier, E., Bergmann, P., Bruyère, O., Delanaye, P., Durnez, A., Devogelaer, J.-P., Ferrari, S. L., Gielen, E., Goemaere, S., Kaufman, J.-M., et al. (2016) · Osteoporosis International

Bone health and osteoporosis researchBone Metabolism and Diseases

Cited by 63

Efficacy and safety profile of SGLT2 inhibitors in the elderly: how is the benefit/risk balance?

Scheen, A. J., & Bonnet, F. (2023) · Diabetes & Metabolism

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 51

The future of obesity: new drugs versus lifestyle interventions

Scheen, A. J. (2008) · Expert Opinion on Investigational Drugs

Pharmacology and Obesity TreatmentObesity, Physical Activity, Diet

Cited by 47

Glucagon, from past to present: a century of intensive research and controversies

Scheen, A. J., & Lefèbvre, P. J. (2023) · The Lancet Diabetes & Endocrinology

Pancreatic function and diabetesDiabetes Treatment and Management

Cited by 44

Reduction of the acute bioavailability of metformin by the α‐glucosidase inhibitor acarbose in normal man

SCHEEN, A. J., FERREIRA ALVES de MAGALHAES, A. C., SALVATORE, T., & LEFEBVRE, P. J. (1994) · European Journal of Clinical Investigation

Diabetes Treatment and ManagementPharmacogenetics and Drug Metabolism

Cited by 42

Hepatic insulin resistance in obese non-diabetic subjects and in type 2 diabetic patients

Paquot, N., Scheen, A. J., Dirlewanger, M., Lefèbvre, P. J., & Tappy, L. (2002) · Obesity Research

Diabetes, Cardiovascular Risks, and LipoproteinsPancreatic function and diabetes

Cited by 37

GLP-1 receptor agonists, body composition, skeletal muscle and risk of sarcopaenia: from promising findings in animal models to debated concern in human studies

Scheen, A. J. (2025) · Diabetes & Metabolism

Nutrition and Health in AgingDiabetes Treatment and Management

Cited by 30